JP7799638B2 - 腫瘍を治療するための薬物 - Google Patents

腫瘍を治療するための薬物

Info

Publication number
JP7799638B2
JP7799638B2 JP2022580273A JP2022580273A JP7799638B2 JP 7799638 B2 JP7799638 B2 JP 7799638B2 JP 2022580273 A JP2022580273 A JP 2022580273A JP 2022580273 A JP2022580273 A JP 2022580273A JP 7799638 B2 JP7799638 B2 JP 7799638B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
endometrial cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022580273A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022002153A5 (https=
JP2023531090A5 (https=
JP2023531090A (ja
Inventor
スー，ナン
チャン，シーチュアン
チェン，ジェ
ワン，シュンチャン
リー，クン
ユー，ディン
ワン，ロンリャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2023531090A publication Critical patent/JP2023531090A/ja
Publication of JPWO2022002153A5 publication Critical patent/JPWO2022002153A5/ja
Publication of JP2023531090A5 publication Critical patent/JP2023531090A5/ja
Application granted granted Critical
Publication of JP7799638B2 publication Critical patent/JP7799638B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022580273A 2020-06-30 2021-06-30 腫瘍を治療するための薬物 Active JP7799638B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202010619111.6 2020-06-30
CN202010620778 2020-06-30
CN202010619083.8 2020-06-30
CN202010619083 2020-06-30
CN202010620778.8 2020-06-30
CN202010619111 2020-06-30
PCT/CN2021/103687 WO2022002153A1 (zh) 2020-06-30 2021-06-30 用于治疗肿瘤的药物

Publications (4)

Publication Number Publication Date
JP2023531090A JP2023531090A (ja) 2023-07-20
JPWO2022002153A5 JPWO2022002153A5 (https=) 2024-07-09
JP2023531090A5 JP2023531090A5 (https=) 2024-07-09
JP7799638B2 true JP7799638B2 (ja) 2026-01-21

Family

ID=79317451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580273A Active JP7799638B2 (ja) 2020-06-30 2021-06-30 腫瘍を治療するための薬物

Country Status (7)

Country Link
US (1) US20230310596A1 (https=)
EP (1) EP4174087A4 (https=)
JP (1) JP7799638B2 (https=)
CN (1) CN115698076A (https=)
AU (1) AU2021301947A1 (https=)
CA (1) CA3188017A1 (https=)
WO (1) WO2022002153A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116209443A (zh) * 2021-08-05 2023-06-02 正大天晴药业集团股份有限公司 治疗小细胞肺癌的药物组合
CN119278053A (zh) * 2022-06-02 2025-01-07 正大天晴药业集团股份有限公司 用于治疗子宫恶性肿瘤的药物组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523786A (ja) 2014-08-05 2017-08-24 シービー セラピューティックス インコーポレイテッド 抗ｐｄ−ｌ１抗体
JP2018515482A (ja) 2015-05-04 2018-06-14 アドヴェンチェン ファーマスーティカルズ，エルエルシー 抗がん剤１−（（４−（４−フルオロ−２−メチル−１ｈ−インドール−５−イロキシ）−６−メトキシキノリン−７−イロキシ）メチル）シクロプロパンアミン、その結晶形及びその塩の調製方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11001631B2 (en) * 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
CN107460221B (zh) * 2016-06-02 2021-01-15 正大天晴药业集团股份有限公司 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
CN110573172A (zh) * 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
EP3577133A1 (en) * 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
US20210147547A1 (en) * 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN113861295B (zh) * 2018-07-20 2024-05-24 厦门大学 抗pd-1抗体及其用途
AU2020212767B2 (en) * 2019-01-25 2025-01-30 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition for treating tumor
CN112168961A (zh) * 2019-07-03 2021-01-05 正大天晴药业集团南京顺欣制药有限公司 治疗结直肠癌的联用药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523786A (ja) 2014-08-05 2017-08-24 シービー セラピューティックス インコーポレイテッド 抗ｐｄ−ｌ１抗体
JP2018515482A (ja) 2015-05-04 2018-06-14 アドヴェンチェン ファーマスーティカルズ，エルエルシー 抗がん剤１−（（４−（４−フルオロ−２−メチル−１ｈ−インドール−５−イロキシ）−６−メトキシキノリン−７−イロキシ）メチル）シクロプロパンアミン、その結晶形及びその塩の調製方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
American Society of Clinical Oncology Educational Book，2020年05月，No. 40，pp. 238-244，DOI: 10.1200/EDBK_280503
International Journal of Gynecological Cancer，2018年，Vol. 28, No. 1，pp. 152-160，DOI: 10.1097/IGC.0000000000001129
Journal of Clinical Oncology，2020年05月，Vol. 38, No. 15_suppl, e15081，DOI: 10.1200/JCO.2020.38.15_suppl.e15081
Journal of Gynecologic Oncology，2019年，Vol. 30, No. 3，pp. 1-20，DOI: 10.3802/jgo.2019.30.e46
Value-Based Cancer Care [online], [text]，2016年，Vol. 7, No. 10，[retrieved on 2025.11.25], <https://www.valuebasedcancer.com/issues/2016/november-2016-vol-7-no-10/pembrolizumab-succeeds-nivolumab-fails-as-first-line-therapy-for-advanced-nsclc>

Also Published As

Publication number Publication date
EP4174087A4 (en) 2024-08-07
AU2021301947A1 (en) 2023-02-16
EP4174087A1 (en) 2023-05-03
CA3188017A1 (en) 2022-01-06
CN115698076A (zh) 2023-02-03
US20230310596A1 (en) 2023-10-05
WO2022002153A1 (zh) 2022-01-06
JP2023531090A (ja) 2023-07-20

Similar Documents

Publication Publication Date Title
US12421313B2 (en) Combined pharmaceutical composition for treating tumor
US12527784B2 (en) Combined pharmaceutical composition for treating small cell lung cancer
CA3091217A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP4442710A1 (en) Drug combination for treating non-small cell lung cancer
CN116370641A (zh) 用于治疗消化系统恶性肿瘤的联用药物
JP7799638B2 (ja) 腫瘍を治療するための薬物
EP4144371A1 (en) Combination drug for treating kidney cancer
CN113018429A (zh) 治疗卵巢癌的药物组合
JP2024527974A (ja) 小細胞肺がんを治療する薬物の組み合わせ
EP4197554A1 (en) Combined medication for treating soft tissue sarcoma
RU2859366C2 (ru) Препарат для лечения опухоли
CN119278053A (zh) 用于治疗子宫恶性肿瘤的药物组合
HK40093427A (en) Drug for treating tumor
RU2829637C2 (ru) Комбинированная фармацевтическая композиция для лечения опухоли
CN117642181A (zh) 用于治疗食管癌的药物组合
US20240316031A1 (en) Combination drug for treatment of gastric carcinoma and/or esophagogastric junction cancer
HK40118252A (en) Drug combination for treating non-small cell lung cancer
CN116036265A (zh) 用于癌症的联用药物
HK40113045A (zh) 治疗肿瘤的联用药物组合物
WO2025087358A1 (zh) 抗体药物偶联物用于治疗癌症的方法
HK40083393A (en) Combination drug for treating kidney cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251226

R150 Certificate of patent or registration of utility model

Ref document number: 7799638

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150